Do analysts recommend BHC or GUD?

Knight Therapeutics has a consensus target price of C$9.50, indicating a potential downside of 3.46%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Knight Therapeutics is more favorable than Bausch Health Companies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Companies 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Knight Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher earnings and valuation, GUD or CRON?

Knight Therapeutics has higher revenue and earnings than Cronos Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Knight Therapeutics C$510.45M 1.89 -C$30.73M C$0.06 164.00 Cronos Group C$159.54M 9.37 -C$32.78M N/A N/A

Which has preferable earnings and valuation, GUD or THCX?

Hydropothecary has lower revenue, but higher earnings than Knight Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Knight Therapeutics C$510.45M 1.89 -C$30.73M C$0.06 164.00 Hydropothecary N/A N/A N/A N/A N/A

Knight Therapeutics (GUD) Competitors

C$9.84 +0.02 (+0.20%)

As of 07/28/2026 04:00 PM Eastern

Compare

GUD vs. BHC, CRON, DHT.UN, THCX, and TLRY

Should you buy Knight Therapeutics stock or one of its competitors? MarketBeat compares Knight Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Knight Therapeutics include Bausch Health Companies (BHC), Cronos Group (CRON), DRI Healthcare Trust (DHT.UN), Hydropothecary (THCX), and Tilray Brands (TLRY). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Knight Therapeutics compare to Bausch Health Companies?

Bausch Health Companies (TSE:BHC) and Knight Therapeutics (TSE:GUD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Knight Therapeutics has a net margin of 1.10% compared to Bausch Health Companies' net margin of -13.54%. Bausch Health Companies' return on equity of 120.43% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Companies	-13.54%	120.43%	4.16%
Knight Therapeutics	1.10%	0.73%	0.51%

In the previous week, Bausch Health Companies had 17 more articles in the media than Knight Therapeutics. MarketBeat recorded 17 mentions for Bausch Health Companies and 0 mentions for Knight Therapeutics. Bausch Health Companies' average media sentiment score of 0.78 beat Knight Therapeutics' score of 0.00 indicating that Bausch Health Companies is being referred to more favorably in the media.

Company	Overall Sentiment
Bausch Health Companies	Positive
Knight Therapeutics	Neutral

Knight Therapeutics has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Companies	C$10.53B	0.23	-C$125.65M	-C$3.24	N/A
Knight Therapeutics	C$510.45M	1.89	-C$30.73M	C$0.06	164.00

Knight Therapeutics has a consensus target price of C$9.50, indicating a potential downside of 3.46%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Knight Therapeutics is more favorable than Bausch Health Companies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Companies	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Bausch Health Companies has a beta of 0.973491, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.206788, suggesting that its share price is 121% less volatile than the broader market.

10.7% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 23.0% of Knight Therapeutics shares are owned by institutional investors. 11.3% of Bausch Health Companies shares are owned by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Knight Therapeutics beats Bausch Health Companies on 10 of the 16 factors compared between the two stocks.

How does Knight Therapeutics compare to Cronos Group?

Knight Therapeutics (TSE:GUD) and Cronos Group (TSE:CRON) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Knight Therapeutics presently has a consensus price target of C$9.50, indicating a potential downside of 3.46%. Cronos Group has a consensus price target of C$4.75, indicating a potential upside of 18.75%. Given Cronos Group's higher probable upside, analysts plainly believe Cronos Group is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Knight Therapeutics has a beta of -0.206788, indicating that its share price is 121% less volatile than the broader market. Comparatively, Cronos Group has a beta of 1.126226, indicating that its share price is 13% more volatile than the broader market.

23.0% of Knight Therapeutics shares are held by institutional investors. Comparatively, 4.3% of Cronos Group shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by insiders. Comparatively, 46.4% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Knight Therapeutics has a net margin of 1.10% compared to Cronos Group's net margin of -1.29%. Knight Therapeutics' return on equity of 0.73% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Knight Therapeutics	1.10%	0.73%	0.51%
Cronos Group	-1.29%	-0.19%	-3.73%

In the previous week, Knight Therapeutics' average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company	Overall Sentiment
Knight Therapeutics	Neutral
Cronos Group	Neutral

Knight Therapeutics has higher revenue and earnings than Cronos Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Knight Therapeutics	C$510.45M	1.89	-C$30.73M	C$0.06	164.00
Cronos Group	C$159.54M	9.37	-C$32.78M	N/A	N/A

Summary

Knight Therapeutics beats Cronos Group on 7 of the 12 factors compared between the two stocks.

How does Knight Therapeutics compare to DRI Healthcare Trust?

Knight Therapeutics (TSE:GUD) and DRI Healthcare Trust (TSE:DHT.UN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Knight Therapeutics presently has a consensus target price of C$9.50, indicating a potential downside of 3.46%. DRI Healthcare Trust has a consensus target price of C$24.80, indicating a potential upside of 39.95%. Given DRI Healthcare Trust's stronger consensus rating and higher probable upside, analysts clearly believe DRI Healthcare Trust is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

DRI Healthcare Trust has lower revenue, but higher earnings than Knight Therapeutics. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Knight Therapeutics	C$510.45M	1.89	-C$30.73M	C$0.06	164.00
DRI Healthcare Trust	C$163.77M	5.95	C$9.73M	-C$0.90	N/A

Knight Therapeutics has a beta of -0.206788, suggesting that its share price is 121% less volatile than the broader market. Comparatively, DRI Healthcare Trust has a beta of 0.385191, suggesting that its share price is 61% less volatile than the broader market.

DRI Healthcare Trust has a net margin of 5.02% compared to Knight Therapeutics' net margin of 1.10%. DRI Healthcare Trust's return on equity of 2.06% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Knight Therapeutics	1.10%	0.73%	0.51%
DRI Healthcare Trust	5.02%	2.06%	4.22%

In the previous week, Knight Therapeutics' average media sentiment score of 0.00 equaled DRI Healthcare Trust'saverage media sentiment score.

Company	Overall Sentiment
Knight Therapeutics	Neutral
DRI Healthcare Trust	Neutral

23.0% of Knight Therapeutics shares are owned by institutional investors. Comparatively, 0.8% of DRI Healthcare Trust shares are owned by institutional investors. 45.6% of Knight Therapeutics shares are owned by insiders. Comparatively, 0.1% of DRI Healthcare Trust shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

DRI Healthcare Trust beats Knight Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Knight Therapeutics compare to Hydropothecary?

Knight Therapeutics (TSE:GUD) and Hydropothecary (CVE:THCX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Knight Therapeutics presently has a consensus target price of C$9.50, suggesting a potential downside of 3.46%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Knight Therapeutics is more favorable than Hydropothecary.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Hydropothecary	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Hydropothecary has lower revenue, but higher earnings than Knight Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Knight Therapeutics	C$510.45M	1.89	-C$30.73M	C$0.06	164.00
Hydropothecary	N/A	N/A	N/A	N/A	N/A

In the previous week, Knight Therapeutics' average media sentiment score of 0.00 equaled Hydropothecary'saverage media sentiment score.

Company	Overall Sentiment
Knight Therapeutics	Neutral
Hydropothecary	Neutral

Knight Therapeutics has a net margin of 1.10% compared to Hydropothecary's net margin of 0.00%. Knight Therapeutics' return on equity of 0.73% beat Hydropothecary's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Knight Therapeutics	1.10%	0.73%	0.51%
Hydropothecary	N/A	N/A	N/A

23.0% of Knight Therapeutics shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Knight Therapeutics beats Hydropothecary on 9 of the 9 factors compared between the two stocks.

How does Knight Therapeutics compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Tilray Brands has a beta of 3.0845, suggesting that its stock price is 208% more volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.206788, suggesting that its stock price is 121% less volatile than the broader market.

4.4% of Tilray Brands shares are held by institutional investors. Comparatively, 23.0% of Knight Therapeutics shares are held by institutional investors. 0.7% of Tilray Brands shares are held by insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Tilray Brands had 1 more articles in the media than Knight Therapeutics. MarketBeat recorded 1 mentions for Tilray Brands and 0 mentions for Knight Therapeutics. Tilray Brands' average media sentiment score of 0.00 equaled Knight Therapeutics'average media sentiment score.

Company	Overall Sentiment
Tilray Brands	Neutral
Knight Therapeutics	Neutral

Knight Therapeutics has a net margin of 1.10% compared to Tilray Brands' net margin of -158.75%. Knight Therapeutics' return on equity of 0.73% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-158.75%	-88.06%	-1.41%
Knight Therapeutics	1.10%	0.73%	0.51%

Tilray Brands currently has a consensus target price of C$13.30, indicating a potential upside of 134.15%. Knight Therapeutics has a consensus target price of C$9.50, indicating a potential downside of 3.46%. Given Tilray Brands' higher possible upside, equities analysts clearly believe Tilray Brands is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Knight Therapeutics has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	C$858.28M	0.82	-C$183.24M	-C$14.63	N/A
Knight Therapeutics	C$510.45M	1.89	-C$30.73M	C$0.06	164.00

Summary

Knight Therapeutics beats Tilray Brands on 11 of the 15 factors compared between the two stocks.

Get Knight Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GUD vs. The Competition

Export

Metric	Knight Therapeutics	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$964.12M	C$5.52B	C$7.08B	C$13.02B
Dividend Yield	N/A	2.81%	2.66%	6.19%
P/E Ratio	164.00	5.11	27.28	36.56
Price / Sales	1.89	1,643.50	578.34	9.44
Price / Cash	3.85	10.18	49.60	82.29
Price / Book	1.23	10.39	10.13	4.38
Net Income	-C$30.73M	C$20.27B	C$3.60B	C$299.09M
7 Day Performance	1.65%	-0.34%	-0.95%	-0.88%
1 Month Performance	1.44%	-0.62%	-3.60%	0.12%
1 Year Performance	60.26%	6.89%	20.53%	30.04%

Knight Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GUD Knight Therapeutics	N/A	C$9.84 +0.2%	C$9.50 -3.5%	+60.0%	C$964.12M	C$510.45M	164.00	725
BHC Bausch Health Companies	0.7121 of 5 stars	C$6.36 -1.2%	N/A	-32.3%	C$2.38B	C$10.53B	N/A	19,900	Trending News Analyst Revision
CRON Cronos Group	1.7546 of 5 stars	C$3.83 -2.3%	C$4.75 +24.0%	+41.3%	C$1.43B	C$159.54M	N/A	450	News Coverage
DHT.UN DRI Healthcare Trust	2.0456 of 5 stars	C$17.70 -0.5%	C$24.80 +40.1%	+22.1%	C$973.78M	C$163.77M	N/A	N/A
THCX Hydropothecary	N/A	C$5.30 +6.6%	N/A	+0.0%	C$949.11M	N/A	N/A	N/A	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:GUD) was last updated on 7/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Knight Therapeutics (GUD) Competitors

GUD vs. BHC, CRON, DHT.UN, THCX, and TLRY

How does Knight Therapeutics compare to Bausch Health Companies?

Summary

How does Knight Therapeutics compare to Cronos Group?

Summary

How does Knight Therapeutics compare to DRI Healthcare Trust?

Summary

How does Knight Therapeutics compare to Hydropothecary?

Summary

How does Knight Therapeutics compare to Tilray Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUD vs. The Competition

Knight Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Knight Therapeutics (GUD) Competitors

GUD vs. BHC, CRON, DHT.UN, THCX, and TLRY

How does Knight Therapeutics compare to Bausch Health Companies?

Is BHC or GUD more profitable?

Does the media favor BHC or GUD?

Which has higher valuation & earnings, BHC or GUD?

Do analysts recommend BHC or GUD?

Which has more risk & volatility, BHC or GUD?

Do insiders and institutionals have more ownership in BHC or GUD?

Summary

How does Knight Therapeutics compare to Cronos Group?

Do analysts recommend GUD or CRON?

Which has more risk and volatility, GUD or CRON?

Do insiders & institutionals have more ownership in GUD or CRON?

Is GUD or CRON more profitable?

Does the media prefer GUD or CRON?

Which has higher earnings and valuation, GUD or CRON?

Summary

How does Knight Therapeutics compare to DRI Healthcare Trust?

Do analysts recommend GUD or DHT.UN?

Which has better earnings and valuation, GUD or DHT.UN?

Which has more volatility and risk, GUD or DHT.UN?

Is GUD or DHT.UN more profitable?

Does the media refer more to GUD or DHT.UN?

Do insiders and institutionals believe in GUD or DHT.UN?

Summary

How does Knight Therapeutics compare to Hydropothecary?

Do analysts recommend GUD or THCX?

Which has preferable earnings and valuation, GUD or THCX?

Does the media refer more to GUD or THCX?

Is GUD or THCX more profitable?

Do insiders & institutionals hold more shares of GUD or THCX?

Summary

How does Knight Therapeutics compare to Tilray Brands?

Which has more volatility & risk, TLRY or GUD?

Do institutionals & insiders have more ownership in TLRY or GUD?

Does the media favor TLRY or GUD?

Is TLRY or GUD more profitable?

Do analysts prefer TLRY or GUD?

Which has preferable valuation and earnings, TLRY or GUD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUD vs. The Competition

Knight Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools